Oncology Advertising

Article

For the past 25 years ONCOLOGY has kept pace with the progression of the oncology field and has offered an interpretation of literature which appeals to both the academician and the practicing "in-the-trenches" community oncologist. Its unique editorial platform consists of clinical and practical review articles followed by 2-3 expert commentaries. The journal's review articles are authored by top physicians in their respective specialties and address important issues and questions such as: interpretations and reviews of the latest and sometimes controversial-research; and new "takes" on persistent unresolved problems. Editorial features such as Practice & Policy, explore the changing times in the healthcare landscape in such areas as FDA regulations, Medicare & Medicaid policy, and the impact of health care reform. Another feature is Integrative Oncology which covers alternative herbal treatments, uses, research, adverse reactions and interactions. ONCOLOGY serves as a strong resource and forum for the cancer care clinician and generates a strong sense of community among its readers. Click here to view our media kit/rate card.Publisher and Sales Contacts:Amy BirnbachGroup PublisherPh: 201-984-6265Email: amy.birnbach@ubm.comSarah MifsudAccount ManagerDigital MediaPh: 203-523-7055Email: sarah.mifsud@ubm.com

ADVERTISING

For the past 25 years ONCOLOGY has kept pace with the progression of the oncology field and has offered an interpretation of literature which appeals to both the academician and the practicing "in-the-trenches" community oncologist.

Its unique editorial platform consists of clinical and practical review articles followed by 2-3 expert commentaries. The journal's review articles are authored by top physicians in their respective specialties and address important issues and questions such as: interpretations and reviews of the latest and sometimes controversial-research; and new "takes" on persistent unresolved problems.

Editorial features such as Practice & Policy, explore the changing times in the healthcare landscape in such areas as FDA regulations, Medicare & Medicaid policy, and the impact of health care reform. Another feature is Integrative Oncology which covers alternative herbal treatments, uses, research, adverse reactions and interactions.

ONCOLOGY
serves as a strong resource and forum for the cancer care clinician and generates a strong sense of community among its readers.

Click here to view our media kit/rate card.

Publisher and Sales Contacts:
Amy Birnbach
Group Publisher
Ph: 201-984-6265
Email: amy.birnbach@ubm.com

Sarah Mifsud
Account Manager
Digital Media
Ph: 203-523-7055
Email: sarah.mifsud@ubm.com

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content